SecBot SecBot
8-K ·Filed Jun 12, 2026

RCKT

ROCKET PHARMACEUTICALS, INC.
BULLISH
Impact 5/10
Horizonimmediate Processed5mo ago SEC0001140361-26-024997
8-K material event: Items 2.01
Actionable Insight ▲ Bullish

The closing removes completion risk and solidifies the balance sheet. With extended runway into Q2 2028, the company has increased financial flexibility to execute on its cardiovascular gene therapy pipeline. Monitor for upcoming clinical catalysts and potential business development activities enabled by this liquidity.

DirectionBullish
Confidencehigh
Horizonimmediate

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$2.75
T+0 close · Jun 12, 2026 · via day close
Latest settled
+34.91%
T+60 · $3.71
Vs SPY
+31.65%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 12 $2.75entry
  2. T+1 · 5mo ago +4.00%α +2.24% · $2.86
  3. T+5 · 5mo ago +21.82%α +21.15% · $3.35
  4. T+20 · 4mo ago +42.18%α +40.40% · $3.91
  5. T+60 · 2mo ago +34.91%α +31.65% · $3.71
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Rocket Pharmaceuticals completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $180 million in gross proceeds, a previously announced transaction. The non-dilutive capital infusion boosts pro-forma cash to approximately $322.6 million and extends the company's cash runway into the second quarter of 2028, strengthening its balance sheet as it advances its cardiovascular gene therapy pipeline.

Key Facts

  • Completed sale of PRV for $180.0 million in gross proceeds
  • Pro-forma cash, cash equivalents and investments increased to approximately $322.6 million
  • Cash runway extended into Q2 2028
  • Transaction closed on June 10, 2026, announced via press release on June 12, 2026
  • PRV was originally granted by the FDA in March 2026 in connection with KRESLADI approval

Financial Impact

Gross proceeds of $180.0 million added; pre-sale cash was $144.4 million, post-sale pro forma cash ~$322.6 million

cashcash runway

Risk Factors

  • Pipeline execution and clinical trial risks remain
  • Stock may have already priced in the PRV sale from the prior announcement
  • One-time monetization event without recurring revenue impact

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
55% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001140361-26-024997
Document: ef20076119_ex99-1.htm0001140361-26-024997
Document: 0001140361-26-024997-index-headers.html0001140361-26-024997
Document: 0001140361-26-024997-index.html0001140361-26-024997
Document: 0001140361-26-024997.txt0001140361-26-024997

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 12, 2026